Inici › Mieloma múltiple › Florida › Miami
Assaigs clínics de Mieloma múltiple a Miami, FL
21 estudis de Mieloma múltiple busquen participants en centres de Miami i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
ReclutantFase 1/2
- University of Miami, Miami
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ReclutantFase 2
- University of Miami Sylvester Comprehensive Cancer Center, Miami
- University of Miami/Sylvester Cancer Institute - Alex's Place, Miami
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building, Miami
- i 2 més
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
ReclutantFase 2
- University of Miami, Miami
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
ReclutantFase 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 2
- Miami Cancer Institute at Baptist Health, Inc., Miami
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
ReclutantFase 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
- i 3 més
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
ReclutantFase 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics, Miami
- Sylvester Comprehensive Cancer Center - Kendall, Miami
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
ReclutantFase 2
- University of Miami, Miami
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
ReclutantFase 1
- University of Miami Don Soffer Clinical Research Center, Miami
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ReclutantFase 1/2
- Research Site, Miami
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
ReclutantFase 1
- University of Miami, Miami
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
ReclutantFase 4
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
Reclutant
- University of Miami, Miami
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
ReclutantEstudi observacional
- University of Miami Hospitals, Miami
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutantFase 1/2
- University of Miami, Miami
- Miami Cancer Institute, Miami
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
ReclutantFase 2
- University of Miami, Miami
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
ReclutantFase 2
- University of Miami, Miami
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
ReclutantFase 2
- University of Miami, Sylvester Comprehensive Cancer Center, Miami
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Miami Cancer Institute, Miami
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
ReclutantFase 2
- University of Miami, Miami
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
ReclutantFase 1
- Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami
Assaigs de Mieloma múltiple en altres ciutats
- New York City, NY60 estudis
- Boston, MA42 estudis
- Atlanta, GA41 estudis
- Houston, TX38 estudis
- Durham, NC37 estudis
- Nashville, TN32 estudis
- Denver, CO27 estudis
- Rochester, MN24 estudis
- St. Louis, MO24 estudis
- Columbus, OH24 estudis
- Baldwin Park, CA23 estudis
- Chicago, IL22 estudis
Altres estudis a Miami
- Càncer de mama42 estudis
- Càncer (tots els tipus)36 estudis
- Càncer de pulmó de cèl·lules no petites31 estudis
- Càncer de pròstata27 estudis
- Obesitat27 estudis
- Leucèmia mieloide aguda24 estudis
- Càncer metastàtic24 estudis
- Càncer d'ovari23 estudis
- Sobrepès23 estudis
- Colitis ulcerosa21 estudis
- Malaltia d'Alzheimer20 estudis
- Càncer de pulmó20 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.